The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Integrative Clinical Genomics of Advanced Prostate Cancer
Open accessAbstract
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“The consortium utilized two sequencing and analysis centers, one centralized digital pathology review center, and one centralized data visualization portal (Cerami et al., 2012; Gao et al., 2013; Robinson et al., 2011; Thorvaldsdóttir et al., 2013).”
Self-citationRobinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 3×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationTrapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · cited 1×
“…analysis reveals that the majority of affected individuals with metastatic castration-resistant prostate cancer harbor clinically actionable molecular alterations, highlighting the need for genetic counseling to inform precision medicine in affected individuals with advanced prostate cancer.”
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965 · cited 2×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Self-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · cited 1×
“…on the PI3K pathway, PIK3CB-specific inhibitors may have utility in affected individuals with mutation, amplification, and/or fusion of this gene (Schwartz et al., 2015); multiple affected individuals who achieved durable (>1 year) responses to PIK3CB-specificin inhibition harbored activating…”
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Self-citationRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 1×
“Among chimeric fusion transcripts identified, recurrent ETS fusions (Tomlins et al., 2005) were observed in 84 cases (56%), of which the majority were fused to ERG and others to FLI1, ETV4, and ETV5 (Figure 3B).”
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,007
Servant, R., Garioni, M., Vlajnic, T., Blind, M., Pueschel, H., Müller, D. C., Zellweger, T., Templeton, A. J., Garofoli, A., Maletti, S., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5698 · Cited by 82
Self-citationMolecular mechanisms underlying the development of neuroendocrine prostate cancer
Liu, S., Alabi, B. R., Yin, Q., & Stoyanova, T. I. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.007 · Cited by 84
Chi, K. N., Barnicle, A., Sibilla, C., Lai, Z., Corcoran, C., Barrett, J. C., Adelman, C. A., Qiu, P., Easter, A., Dearden, S. P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0931 · Cited by 85
Self-citationShah, S., Carriveau, W. J., Li, J., Campbell, S. L., Kopinski, P. K., Lim, H., Daurio, N. A., Trefely, S., Won, K., Wallace, D. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9666 · Cited by 85
Lotan, T. L., Heumann, A., Rico, S. D., Hicks, J. L., Lecksell, K., Koop, C., Sauter, G., Schlomm, T., & Simon, R. (2017) · Oncotarget · doi:10.18632/oncotarget.19217 · Cited by 82
Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors
Hankey, W., Chen, Z., & Wang, Q. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3447 · Cited by 86
Schweizer, M. T., Sivakumar, S., Tukachinsky, H., Coleman, I. M., Sarkar, N. D., Yu, E. Y., Konnick, E. Q., Nelson, P. S., Pritchard, C. C., & Montgomery, B. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2350 · Cited by 82
Self-citationProstate cancer and the unfolded protein response
Storm, M. L., Sheng, X., Arnoldussen, Y. J., & Saatcioglu, F. (2016) · Oncotarget · doi:10.18632/oncotarget.9912 · Cited by 81
Flores‐Morales, A., Bergmann, T., Lavallee, C., Batth, T. S., Lin, D., Lerdrup, M., Friis, S., Bartels, A., Kristensen, G., Krzyzanowska, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0729 · Cited by 82
Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
Tucci, M., Zichi, C., Buttigliero, C., Vignani, F., Scagliotti, G. V., & Maïo, M. D. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s153764 · Cited by 83
Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
Tucker, M. D., Zhu, J., Marin, D., Gupta, R. T., Gupta, S. K., Berry, W. R., Ramalingam, S., Zhang, T., Harrison, M. R., Wu, Y. S., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2375 · Cited by 82
Self-citationLow Abundance of Circulating Tumor DNA in Localized Prostate Cancer
Hennigan, S. T., Trostel, S. Y., Terrigino, N. T., Voznesensky, O. S., Schaefer, R. J., Whitlock, N. C., Wilkinson, S. C., Carrabba, N. V., Atway, R., Shema, S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00176 · Cited by 83
Self-citationThe FGF/FGFR system in the physiopathology of the prostate gland
Giacomini, A., Grillo, E., Rezzola, S., Ribatti, D., Rusnati, M., Ronca, R., & Presta, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00005.2020 · Cited by 81
Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
Hatano, K., & Nonomura, N. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.220200 · Cited by 81
SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer
Audet‐Walsh, É., Vernier, M., Yee, T., Laflamme, C., Li, S., Chen, Y., & Giguère, V. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0410 · Cited by 82
Self-citationTakayama, K. (2019) · Biomolecules · doi:10.3390/biom9040131 · Cited by 84
Targeting DNA Damage Response in Prostate and Breast Cancer
Wengner, A. M., Scholz, A., & Haendler, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218273 · Cited by 81
Oseni, S. O., Naar, C., Pavlović, M. D., Asghar, W., Hartmann, J. X., Fields, G. B., Esiobu, N., & Kumi-Diaka, J. K. (2023) · Cancers · doi:10.3390/cancers15123110 · Cited by 100
“For instance, inherited mutations of p53, PTEN, HOXB13, BRCA1, and BRCA2 genes have been associated with increased PCa risk and account for most cases of hereditary/familiar PCa [63,64].”
BackgroundPetrovics, G., Li, H., Stümpel, T., Tan, S., Young, D., Katta, S., Li, Q., Ying, K., Klocke, B., Ravindranath, L., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.10.028 · Cited by 79
Self-citationSchweizer, M. T., Wang, H., Luber, B. S., Nadal, R., Spitz, A. N., Rosen, D. M., Cao, H., Antonarakis, E. S., Eisenberger, M. A., Carducci, M. A., et al. (2016) · The Prostate · doi:10.1002/pros.23209 · Cited by 80
Aggarwal, R. R., Quigley, D. A., Huang, J., Zhang, L., Beer, T. M., Rettig, M. B., Reiter, R. E., Gleave, M. E., THOMAS, G. V., Foye, A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1101 · Cited by 80
Self-citationNotch promotes tumor metastasis in a prostate-specific Pten-null mouse model
Kwon, O.-J., Zhang, L., Wang, J., Su, Q., Feng, Q. F., Zhang, X. H.-F., Mani, S. A., Paulter, R., Creighton, C. J., Ittmann, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84637 · Cited by 77
Faugeroux, V., Pailler, E., Oulhen, M., Déas, O., Brullé, L., Hervieu, C., Marty, V., Alexandrova, K., Andree, K., Stoecklein, N. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15426-2 · Cited by 87
Swami, U., Velho, P. I., Nussenzveig, R. H., Chipman, J., Santos, V. S., Erickson, S., Dharmaraj, D., Alva, A. S., Vaishampayan, U. N., Esther, J., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.06.033 · Cited by 79
Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy
Wilkinson, S. C., Ye, H., Karzai, F. H., Harmon, S. A., Terrigino, N. T., VanderWeele, D. J., Bright, J. R., Atway, R., Trostel, S. Y., Carrabba, N. V., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.03.009 · Cited by 79
Self-citationKato, M., Tsuzuki, T., Kimura, K., Hirakawa, A., Kinoshita, F., Sassa, N., Ishida, R., Fukatsu, A., Kimura, T., Funahashi, Y., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2015.146 · Cited by 79
Meisel, A., von Felten, S., Vogt, D., Liewen, H., de Wit, R., Bono, J. S. D., Sartor, O. A., & Stenner, F. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.009 · Cited by 80
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D
Komura, K., Yoshikawa, Y., Shimamura, T., Chakraborty, G., Gerke, T. A., Hinohara, K., Chadalavada, K., Jeong, S. H., Armenia, J., Du, S.-Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96769 · Cited by 80
Self-citationSowalsky, A. G., Ye, H., Bhasin, M., Allen, E. M. V., Loda, M. F., Lis, R. T., Montaser‐Kouhsari, L., Calagua, C., Ma, F., Russo, J. W., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0610 · Cited by 78
Self-citationZafeiriou, Z., Bianchini, D., Chandler, R. W., Rescigno, P., Yuan, W., Carreira, S., Barrero, M., Petremolo, A., Miranda, S., Riisnaes, R., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.048 · Cited by 81
Self-citationBhagirath, D., Yang, T. L., Tabatabai, Z. L., Majid, S., Dahiya, R., Tanaka, Y., & Saini, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0498 · Cited by 80
Malihi, P. D., Graf, R. P., Rodríguez, Á., Ramesh, N., Lee, J. S. H., Sutton, R., Jiles, R., Velasco, C. R., Sei, E., Kolatkar, A. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4100 · Cited by 78
Hamid, A., Huang, H.-C., Wang, V., Chen, Y., Feng, F. Y.-C., Den, R. B., Attard, G., Allen, E. M. V., Tran, P. T., Spratt, D. E., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.003 · Cited by 78
Self-citationProstate zones and cancer: lost in transition?
Ali, A., Feu, A. D., Oliveira, P., Choudhury, A., Bristow, R. G., & Baena, E. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00524-7 · Cited by 83
Understanding Drug Sensitivity and Tackling Resistance in Cancer
Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Ness, B. V., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3695 · Cited by 81
Self-citationTranslational and clinical implications of the genetic landscape of prostate cancer
Spratt, D. E., Zumsteg, Z. S., Feng, F. Y.-C., & Tomlins, S. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.76 · Cited by 78
Self-citationEnzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Linder, S., van der Poel, H. G., Bergman, A. M., Zwart, W. T., & Preković, S. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0289 · Cited by 78
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
Schweizer, M. T., Cheng, H. H., Tretiakova, M., Vakar‐Lopez, F., Klemfuss, N. M., Konnick, E. Q., Mostaghel, E. A., Nelson, P. S., Yu, E. Y., Montgomery, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12697 · Cited by 77
Self-citationTET2 binds the androgen receptor and loss is associated with prostate cancer
Nickerson, M. L., Das, S., Im, K. M., Turan, S., Berndt, S. I., Li, H., Lou, H., Brodie, S. A., Billaud, J.-N., Zhang, T., et al. (2016) · Oncogene · doi:10.1038/onc.2016.376 · Cited by 78
Mazrooei, P., Kron, K. J., Zhu, Y., Zhou, S., Grillo, G., Mehdi, T., Ahmed, M., Severson, T., Guilhamon, P., Armstrong, N. S., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.005 · Cited by 73
Anscher, M. S., Chang, E., Gao, X., Gong, Y. U. T., Weinstock, C., Bloomquist, E. W., Adeniyi, O., Charlab, R., Zimmerman, S., Serlemitsos-Day, M., et al. (2020) · The Oncologist · doi:10.1002/onco.13585 · Cited by 81
African-specific molecular taxonomy of prostate cancer
Jaratlerdsiri, W., Jiang, J., Gong, T., Patrick, S. M., Willet, C. E., Chew, T., Lyons, R. J., Haynes, A., Pasqualim, G., Louw, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05154-6 · Cited by 75
Shi, W. M., Wang, Y., Zhao, Y., Kim, J. J., Li, H., Meng, C., Chen, F., Zhang, J., Mak, D. H. F., Van, V., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf6724 · Cited by 80
Rebello, R. J., Kusnadi, E. P., Cameron, D. P., Pearson, H. B., Lesmana, A., Devlin, J. R., Drygin, D., Clark, A. K., Porter, L. H., Pedersen, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0124 · Cited by 79
Antonarakis, E. S., Chandhasin, C., Osbourne, E., Luo, J., Sadar, M. D., & Perabo, F. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0161 · Cited by 77
Liu, S., Kumari, S., Hu, Q., Senapati, D., Venkadakrishnan, V. B., Wang, D., DePriest, A. D., Schlanger, S. E., Ben‐Salem, S., Valenzuela, M. M., et al. (2017) · eLife · doi:10.7554/elife.28482 · Cited by 75
Wozniak, D. J., Kajdacsy‐Balla, A., Macias, V., Ball-Kell, S. M., Zenner, M. L., Bie, W., & Tyner, A. L. (2017) · Nature Communications · doi:10.1038/s41467-017-01574-5 · Cited by 76
Sumiyoshi, T., Mizuno, K., Yamasaki, T., Miyazaki, Y., Makino, Y., Okasho, K., Li, X., Utsunomiya, N., Goto, T., Kobayashi, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40719-y · Cited by 77
Role of the DNA damage response in prostate cancer formation, progression and treatment
Zhang, W., van Gent, D. C., Incrocci, L., van Weerden, W. M., & Nonnekens, J. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0153-2 · Cited by 79
Ritch, E. J., Fu, S. Y. F., Herberts, C., Wang, G., Warner, E. W., Schönlau, E., Taavitsainen, S., Murtha, A. J., Vandekerkhove, G. R., Beja, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1623 · Cited by 77
Shenderov, E., Boudadi, K., Fu, W., Wang, H., Sullivan, R., Jordan, A., Dowling, D., Harb, R., Schonhoft, J. D., Jendrisak, A., et al. (2021) · The Prostate · doi:10.1002/pros.24110 · Cited by 75
Risbridger, G. P., Clark, A. K., Porter, L. H., Toivanen, R., Bakshi, A., Lister, N. L., Pook, D. W., Pezaro, C. J., Sandhu, S. K., Keerthikumar, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25175-5 · Cited by 79
Han, H. H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110595 · Cited by 74
Self-citationCharacterizing and targeting PDGFRA alterations in pediatric high-grade glioma
Koschmann, C. J., Zamler, D. B., Mackay, A. G., Robinson, D. R., Wu, Y.-M., Doherty, R. E., Marini, B. L., Tran, D., Garton, H. J. L., Muraszko, K. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11602 · Cited by 78
Self-citationBeltran, H., Wyatt, A. W., Chedgy, E. C. P., Donoghue, A., Annala, M., Warner, E. W., Beja, K., Sigouros, M., Mo, F., Fazli, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1034 · Cited by 76
Self-citationTargeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer
Su, Y., Liu, Y., Behrens, C. R., Bidlingmaier, S., Lee, N.-K., Aggarwal, R., Sherbenou, D. W., Burlingame, A. L., Hann, B. C., Simko, J. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121497 · Cited by 82
PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
Nizialek, E. A., & Antonarakis, E. S. (2020) · Cancer Management and Research · doi:10.2147/cmar.s227033 · Cited by 82
Accelerating precision medicine in metastatic prostate cancer
Mateo, J., McKay, R. R., Abida, W. M., Aggarwal, R. R., Alumkal, J. J., Alva, A. S., Feng, F. Y.-C., Gao, X. Y., Graff, J. N., Hussain, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00141-0 · Cited by 76
Self-citationEpigenetics in prostate cancer: clinical implications
Conteduca, V., Hess, J., Yamada, Y., Ku, S., & Beltran, H. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1339 · Cited by 79
Self-citationCurrent and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Henriquez, I., Roach, M., Morgan, T. M., Bossi, A., Gómez, J., Abuchaibe, O., & Couñago, F. (2021) · Biomedicines · doi:10.3390/biomedicines9091247 · Cited by 78
A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity
Swaney, D. L., Ramms, D. J., Wang, Z., Park, J., Goto, Y., Soucheray, M., Bhola, N. E., Kim, K., Zheng, F., Zeng, Y., et al. (2021) · Science · doi:10.1126/science.abf2911 · Cited by 72
Xiang, W., Zhao, L., Han, X., Xu, T., Kregel, S., Wang, M., Miao, B., Qin, C., Wang, M., McEachern, D., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01264 · Cited by 75
Self-citationAR-Signaling in Human Malignancies: Prostate Cancer and Beyond
Schweizer, M. T., & Yu, E. Y. (2017) · Cancers · doi:10.3390/cancers9010007 · Cited by 75
Self-citationMorra, F., Merolla, F., Napolitano, V., Ilardi, G., Miro, C., Paladino, S., Staibano, S., Cerrato, A., & Celetti, A. (2017) · Oncotarget · doi:10.18632/oncotarget.16463 · Cited by 74
Bhanvadia, R. R., VanOpstall, C., Brechka, H., Barashi, N. S., Gillard, M., McAuley, E. M., Vasquez, J. M., Paner, G. P., Chan, W., Andrade, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3673 · Cited by 74
Risbridger, G. P., Toivanen, R., & Taylor, R. A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030536 · Cited by 74
The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP
Hamilton, M. P., Rajapakshe, K., Bader, D. A., Cerne, J. Z., Smith, E. A., Coarfa, C., Hartig, S. M., & McGuire, S. E. (2016) · Neoplasia · doi:10.1016/j.neo.2016.04.008 · Cited by 71
Barbieri, C. E., Chinnaiyan, A. M., Lerner, S. P., Swanton, C., & Rubin, M. A. (2016) · European Urology · doi:10.1016/j.eururo.2016.08.024 · Cited by 74
Self-citationNavigating the evolving therapeutic landscape in advanced prostate cancer
Crawford, E. D., Petrylak, D. P., & Sartor, O. A. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.01.020 · Cited by 77
GOLM1 promotes prostate cancer progression through activating PI3K‐AKT‐mTOR signaling
Yan, G., Ru, Y., Wu, K., Yan, F., Wang, Q., Wang, J., Pan, T., Zhang, M., Han, H., Li, X., et al. (2017) · The Prostate · doi:10.1002/pros.23461 · Cited by 73
Yang, Y., Bai, Y., He, Y., Zhao, Y., Chen, J., Ma, L., Pan, Y., Hinten, M., Zhang, J., Karnes, R. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2006 · Cited by 71
A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer
Wu, Y., Yu, H., Zheng, S. L., Na, R., Mamawala, M. K., Landis, T., Wiley, K. E., Petkewicz, J., Shah, S., Shi, Z., et al. (2018) · The Prostate · doi:10.1002/pros.23505 · Cited by 71
Self-citationTan, S., Petrovics, G., & Srivastava, S. K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041255 · Cited by 77
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy
Conteduca, V., Ku, S., Puca, L., Slade, M. M., Fernandez, L., Hess, J., Bareja, R., Vlachostergios, P. J., Sigouros, M., Mosquera, J. M., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0926 · Cited by 73
Self-citationSOX2 mediates metabolic reprogramming of prostate cancer cells
de Wet, L., Williams, A. J., Gillard, M., Kregel, S., Lamperis, S. M., Gutgesell, L. C., Vellky, J. E., Brown, R. M., Conger, K. O., Paner, G. P., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02157-x · Cited by 77
Wang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022) · PubMed · Cited by 88
Attard, G., Agarwal, N., Graff, J. N., Sandhu, S. K., Efstathiou, E., Özgüroğlu, M., Gomes, A. J., Vianna, K., Luo, H., Gotto, G. T., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03961-8 · Cited by 80
Self-citationPersistent androgen receptor addiction in castration-resistant prostate cancer
Schweizer, M. T., & Yu, E. Y. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0225-2 · Cited by 77
Self-citationOncogenic microRNA-4534 regulates PTEN pathway in prostate cancer
Nip, H., Dar, A. A., Saini, S., Colden, M., Shahryari, V., Chowdhary, H., Yamamura, S., Mitsui, Y., Tanaka, Y., Kato, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12031 · Cited by 73
Ruan, D., He, J., Li, C., Lee, H.-J., Liu, J., Lin, H.-K., & Chan, C. (2017) · Oncogene · doi:10.1038/onc.2017.64 · Cited by 72
Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies
Bujanda, Z. A. L., & Drake, C. G. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-491rr · Cited by 74
Bone biopsy protocol for advanced prostate cancer in the era of precision medicine
Sailer, V., Schiffman, M. H., Kossaï, M., Cyrta, J., Beg, S., Sullivan, B., Pua, B. B., Lee, K. S., Talenfeld, A. D., Nanus, D. M., et al. (2017) · Cancer · doi:10.1002/cncr.31173 · Cited by 73
Self-citationArmstrong, A. J., Lin, P., Higano, C. S., Sternberg, C. N., Sonpavde, G., Tombal, B., Templeton, A. J., Fizazi, K., Phung, D., Wong, E. K., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy406 · Cited by 71
Barnard, M., Quanson, J. L., Mostaghel, E., Pretorius, E., Snoep, J. L., & Storbeck, K.-H. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.06.013 · Cited by 72
Self-citationYang, Y., Blee, A. M., Wang, D., An, J., Pan, Y., Yan, Y., Ma, T., He, Y., Dugdale, J. A., Hou, X., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0686 · Cited by 73
Pawar, A., Gollavilli, P. N., Wang, S., & Asangani, I. A. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.011 · Cited by 77
Pellegrino, B., Mateo, J., Serra, V., & Balmañà, J. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000480 · Cited by 72
Self-citationKim, D., Sun, D., Storck, W. K., Leng, K. W., Jenkins, C., Coleman, D. J., Sampson, D., Guan, X., Kumaraswamy, A., Rodansky, E. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4968 · Cited by 73
Self-citationGenetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
Ghose, A., Moschetta, M., Pappas‐Gogos, G., Sheriff, M., & Boussios, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189783 · Cited by 74
Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2–WNT Signaling Axis
Nandana, S., Tripathi, M., Duan, P., Chu, C.-Y., Mishra, R., Liu, C., Jin, R., Yamashita, H., Zayzafoon, M., Bhowmick, N. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0497 · Cited by 73
CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer
Bastos, D. A., & Antonarakis, E. S. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1427068 · Cited by 71
Rennier, K. R., Krug, E., Virdi, G., Shin, W. J., & Pachynski, R. K. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4245 · Cited by 70
Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications
Brandão, A., Paulo, P., & Teixeira, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145036 · Cited by 74
ATM: Functions of ATM Kinase and Its Relevance to Hereditary Tumors
Ueno, S., Sudo, T., & Hirasawa, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010523 · Cited by 75
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer
Frieling, J. S., Tordesillas, L., Bustos, X., Ramello, M. C., Bishop, R. T., Cianne, J., Snedal, S. A., Li, T., Lo, C. H., de la Iglesia, J. V., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf0108 · Cited by 72
“…prostate tumors, we analyzed the SU2C/PCF dataset that contained metastatic bone and soft tissue tumor biopsies from 118 mCRPC individuals ( 24 ) to measure expression levels of 14 TCR-γ genes ( TRGV9 , TRGV10 , TRGVB , TRGV7 , TRGV4 , TRGV5 , TRGV2 , TRGV3 , TRGVA , TRGV6 , TRGV5P ,…”
Androgen receptor‐related diseases: what do we know?
Shukla, G. C., Plaga, A. R., Shankar, E., & Gupta, S. (2016) · Andrology · doi:10.1111/andr.12167 · Cited by 77
Li, Q., Ye, L., Zhang, X., Wang, M., Lin, C., Huang, S., Guo, W., Lai, Y., Du, H., Li, J., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.029 · Cited by 71
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
Antonarakis, E. S., & Boudadi, K. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34534 · Cited by 101
Naidoo, K., Wai, P. T., Maguire, S. L., Daley, F. M., Haider, S. A., Kriplani, D., Campbell, J., Mirza, H., Grigoriadis, A. E., Tutt, A. N. J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0760 · Cited by 72
Fletcher, C. E., Sulpice, E., Combe, S., Shibakawa, A., Leach, D. A., Hamilton, M. P., Chrysostomou, S., Sharp, A., Welti, J. C., Yuan, W., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0823-5 · Cited by 70
Metadata
- Authors
- Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., Beltran, H., Abida, W., Bradley, R. K., Vinson, J., Cao, X., Vats, P., Kunju, L. P., Hussain, M., Feng, F. Y., Tomlins, S. A., Cooney, K. A., Smith, D. C., Brennan, C., Siddiqui, J., Mehra, R., Chen, Y., Rathkopf, D. E., Morris, M. J., Solomon, S. B., Durack, J. C., Reuter, V. E., Gopalan, A., Gao, J., Loda, M., Lis, R. T., Bowden, M., Balk, S. P., Gaviola, G., Sougnez, C., Gupta, M., Yu, E. Y., Mostaghel, E. A., Cheng, H. H., Mulcahy, H., True, L. D., Plymate, S. R., Dvinge, H., Ferraldeschi, R., Flohr, P., Miranda, S., Zafeiriou, Z., Tunariu, N., Mateo, J., Perez-Lopez, R., Demichelis, F., Robinson, B. D., Schiffman, M., Nanus, D. M., Tagawa, S. T., Sigaras, A., Eng, K. W., Elemento, O., Sboner, A., Heath, E. I., Scher, H. I., Pienta, K. J., Kantoff, P., de Bono, J. S., Rubin, M. A., Nelson, P. S., Garraway, L. A., Sawyers, C. L., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Memorial Sloan Kettering Cancer Center (US)
- NewYork–Presbyterian Hospital (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- Royal Marsden NHS Foundation Trust (GB)
- Howard Hughes Medical Institute (US)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- University of Washington Medical Center (US)
- University of Trento (IT)
- Cornell University (US)
- Wayne State University (US)
- Johns Hopkins University (US)
- Corresponding author
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- ORCID
- Robinson, Dan
- Schultz, Nikolaus
- Mosquera, Juan-Miguel
- Montgomery, Bruce
- Taplin, Mary-Ellen
- Pritchard, Colin C.
- Attard, Gerhardt
- Beltran, Himisha
- Abida, Wassim
- Bradley, Robert K.
- Vinson, Jake
- Cao, Xuhong
- Vats, Pankaj
- Kunju, Lakshmi P.
- Hussain, Maha
- Feng, Felix Y.
- Tomlins, Scott A.
- Cooney, Kathleen A.
- Smith, David C.
- Brennan, Christine
- Siddiqui, Javed
- Mehra, Rohit
- Chen, Yu
- Rathkopf, Dana E.
- Morris, Michael J.
- Solomon, Stephen B.
- Durack, Jeremy C.
- Gopalan, Anuradha
- Gao, Jianjiong
- Loda, Massimo
- Lis, Rosina T.
- Bowden, Michaela
- Gupta, Manaswi
- Yu, Evan Y.
- Mostaghel, Elahe A.
- Cheng, Heather H.
- Mulcahy, Hyojeong
- True, Lawrence D.
- Plymate, Stephen R.
- Dvinge, Heidi
- Flohr, Penny
- Miranda, Susana
- Zafeiriou, Zafeiris
- Tunariu, Nina
- Demichelis, Francesca
- Robinson, Brian D.
- Schiffman, Marc
- Nanus, David M.
- Tagawa, Scott T.
- Sigaras, Alexandros
- Eng, Kenneth W.
- Elemento, Olivier
- Sboner, Andrea
- Heath, Elisabeth I.
- Scher, Howard I.
- Pienta, Kenneth J.
- Kantoff, Philip
- Rubin, Mark A.
- Nelson, Peter S.
- Garraway, Levi A.
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 161
- Issue
- 5
- Pages
- 1215-1228
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4484602
- OpenAlex
- W1578291413
- Cited by
- 3,645
- References
- 64
- Citations by year
- 2026: 178 · 2025: 258 · 2024: 320 · 2023: 363 · 2022: 360 · 2021: 392 · 2020: 378 · 2019: 346 · 2018: 358 · 2017: 355 · 2016: 263 · 2015: 63
- FWCI
- 273.95
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-07-16)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Iris (University of Trento) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Cancer Research UK (13239)
- National Institute for Health and Care Research (CL-2008-22-001)
- Prostate Cancer UK (CEO13_2-002, PG12-49)
- National Institutes of Health (DP2OD002750)
- Medical Research Council (MR/M003272/1)
- National Human Genome Research Institute (UM1HG006508)
- National Cancer Institute (P50 CA 90381, R01CA136578, L30 CA111031, K08CA188615, R21CA128352, U01CA111275, P50CA090381, R01CA131945, UO1CA111275, L30 CA103810, R01CA116337, R01CA129435, P50CA069568, K08CA115927, R01CA092629, R01CA155169, R01CA193910, R01CA085912, P30CA008748, P01CA163227, P50CA097186, P50CA186786, P50CA092629, P30CA006516, R01CA193837)
- National Institute of General Medical Sciences (T32GM007266, R01GM107427)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- metastatic castration-resistant prostate cancer, exome sequencing, transcriptome sequencing, actionable genomic alterations, androgen receptor alterations, ETS gene fusions, TP53, PTEN, R-spondin, APC, β-catenin, BRCA2, BRCA1, ATM, germline pathogenic variants, precision medicine
- MeSH terms
- Humans, Male, Mutation, Neoplasm Metastasis, Cohort Studies, Gene Expression Profiling, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
